Minimally invasive insertion of an equine stented pulmonary valve with a built‐in sinus portion in a sheep model

Dodge‐Khatami, Ali; Hallhagen, Stefan; Limacher, Kuno; Söderberg, Björn; Jenni, Rolf

doi:10.1002/ccd.23354

Cited by 7 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The original search by Uiterwijk et al 20 identified 817 articles, of which 80 were included in qualitative analysis for this study, after reassessment of studies that reported on additional data from previously reported animals ( Supplemental Figure 1 ). All 80 studies 37 , 39 , 40 , 41 , 42 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 ,…”

Section: Resultsmentioning

confidence: 99%

Calcification in Pulmonary Heart Valve Tissue Engineering

Valk

Fomina

Uiterwijk

et al. 2023

JACC: Basic to Translational Science

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Calcification in Pulmonary Heart Valve Tissue Engineering

Valk

Fomina

Uiterwijk

et al. 2023

JACC: Basic to Translational Science

View full text Add to dashboard Cite

“…So far, only two studies have reported the implementation of Valsalva sinuses into TEHVs. 20,62 Dodge–Khatami and colleagues 62 used decellularized equine valved jugular veins as TPVR in sheep, showing promising functionality and endothelialization potential. However, the use of non-fixed xenogeneic material may represent a significant limitation for their future clinical translation.…”

Section: Discussionmentioning

confidence: 99%

Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements

et al. 2019

View full text Add to dashboard Cite

Transcatheter valve replacement indication is currently being extended to younger and lower-risk patients. However, transcatheter prostheses are still based on glutaraldehyde-fixed xenogeneic materials. Hence, they are prone to calcification and long-term structural degeneration, which are particularly accelerated in younger patients. Tissue-engineered heart valves based on decellularized in vitro grown tissue-engineered matrices (TEM) have been suggested as a valid alternative to currently used bioprostheses, showing good performance and remodeling capacity as transcatheter pulmonary valve replacement (TPVR) in sheep. Here, we first describe the in vitro development of human cell-derived TEM (hTEM) and their application as tissue-engineered sinus valves (hTESVs), endowed with Valsalva sinuses for TPVR. The hTEM and hTESVs were systematically characterized in vitro by histology, immunofluorescence, and biochemical analyses, before they were evaluated in a pulse duplicator system under physiological pulmonary pressure conditions. Thereafter, transapical delivery of hTESVs was tested for feasibility and safety in a translational sheep model, achieving good valve performance and early cellular infiltration. This study demonstrates the principal feasibility of clinically relevant hTEM to manufacture hTESVs for TPVR.

show abstract

“…However, surgically augmented RVOTs can vary considerably in their geometry and dimensions [53], and undergo complex and sometimes extreme deformation during the cardiac cycle [54], which can present a unique set of challenges when it comes to developing devices that are feasible and effective for a wide population of patients. Early preclinical experience with other TPV devices, some designed for large outflow tracts, has also been described [55][56][57][58][59][60].…”

Section: Expanded Applications and The Future Of Tpv Replacementmentioning

confidence: 99%

Transcatheter Pulmonary Valve Replacement: A Current Review

Gillespie

McElhinney

2013

Curr Pediatr Rep

View full text Add to dashboard Cite

Since first reported in 2000, transcatheter (percutaneous) pulmonary valve (TPV) replacement has become an important tool for the management postoperative right ventricular outflow tract (RVOT) dysfunction in patients with congenital heart disease, either as alternative or adjunct to surgery. Implantation of a pulmonary valve for treatment of RVOT obstruction or pulmonary regurgitation without performing open-heart surgery offers obvious appeal, and short-term results from multiple institutions throughout the world support the effectiveness and safety of this therapy. At present, there are two TPV prostheses available in the U.S.: the Medtronic Melody Ò valve is available commercially, and the Edwards Sapien Ò valve is available at limited centers as part of an investigational protocol. Although TPV therapy is likely to have a major impact on the management of postoperative RVOT dysfunction in patients with congenital heart disease or a Ross procedure, the technology is young and there is much that remains to be learned.

show abstract

Minimally invasive insertion of an equine stented pulmonary valve with a built‐in sinus portion in a sheep model

Abstract: The newly developed hydraulic release system allowed for safe and reliable insertion of an equine stented-valve with a sinus portion, through a right transventricular approach on a beating heart, in a sheep survival model.

Cited by 7 publications

References 11 publications

Calcification in Pulmonary Heart Valve Tissue Engineering

Calcification in Pulmonary Heart Valve Tissue Engineering

Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements

Transcatheter Pulmonary Valve Replacement: A Current Review

Contact Info

Product

Resources

About